

Table SI. Progression-free survival by tumor grade.

Tumor grade	Patients, n (%)	Progression-free survival, months (min-max)	P-value
Grade 1-2	1 (3.1)	10 (10-10)	
Grade 2	4 (12.1)	21 (5-36)	
Grade 2-3	3 (9.1)	3 (3-10)	
Grade 3	25 (75.7)	5 (1-17)	
Overall	33 (100)		0.103

Log-rank test was used for statistical analysis.

Table SII. Clinical response rates by tumor grade.

Tumor grade	Patients, n (%)	Partial response, n (%)	Stable disease, n (%)	Progressive disease, n (%)	P-value
<3	8 (24.3)	3 (9.1)	3 (9.1)	2 (6.1)	
3	25 (75.7)	3 (9.1)	6 (18.2)	16 (48.4)	
Overall	33 (100)	6 (18.2)	9 (27.3)	18 (54.5)	0.069

Fisher's exact test was used for statistical analysis.

Table SIII. Progression-free survival by line of pazopanib therapy administered.

Line of treatment	Patients, n (%)	Median progression-free survival, months, (min- max)	P-value
1st	3 (3.7)	23 (9-36)	
2nd	26 (32.5)	5 (3.8-6.1)	
3rd	35 (43.7)	5 (3.4-6.6)	
4th	13 (16.2)	3 (1.2-4.76)	
5th	3 (3.7)	7.5 (0-16.3)	
Overall	80 (100)		0.103

Log-rank test was used for statistical analysis.

Table SIV. Clinical response rates by line of pazopanib therapy administered.

Line of treatment	Patients, n (%)	Partial response, n (%)	Stable disease, n (%)	Progressive disease, n (%)	P-value
1st-2nd	29 (36.25)	5 (6.25)	10 (12.50)	14 (17.50)	
3rd	35 (43.75)	9 (11.25)	9 (11.25)	17 (21.25)	
4th-5th	16 (20.00)	1 (1.25)	3 (3.75)	12 (15.00)	
Overall	80 (100)	15 (18.75)	22 (27.50)	43 (53.75)	0.053

χ^2 test was used for statistical analysis.